Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20749087 | 0.89 | ALDH1A1 (0.53) | ALDH1A1TSHRTDP1HPGDNPC1 | |
| SCHEMBL28912669 | 0.88 | ALDH1A1 (0.51) | ALDH1A1TSHRTDP1HPGDNPC1 | |
| SCHEMBL27258885 | 0.86 | TDP1 (0.56) | ALDH1A1TSHRTDP1HPGDNPC1 | |
| SCHEMBL7135820 | 0.85 | ALDH1A1 (0.60) | ALDH1A1TSHRTDP1HPGDNPC1 | |
| SCHEMBL261866 | 0.83 | ALDH1A1 (0.58) | ALDH1A1TSHRTDP1HPGDNPC1 | |
| SCHEMBL12064619 | 0.82 | ALDH1A1 (0.53) | ALDH1A1TSHRTDP1HPGDNPC1 | |
| SCHEMBL8393234 | 0.82 | ALDH1A1 (0.53) | ALDH1A1TSHRTDP1HPGDNPC1 | |
| SCHEMBL3202573 | 0.82 | ALDH1A1 (0.72) | ALDH1A1TSHRTDP1HPGDNPC1 | |
| SCHEMBL8957406 | 0.81 | ALDH1A1 (0.56) | ALDH1A1TSHRTDP1HPGDNPC1 | |
| SCHEMBL17339105 | 0.81 | ALDH1A1 (0.56) | ALDH1A1TSHRTDP1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704130-A1 | SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF | Melinta Therapeutics, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3615544-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018197663-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018167270-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2018-09-20 | — | — | WO | disclosed |
| EP-3140310-A1 | SYNTHESIS OF BORONATE SALTS AND USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015171430-A1 | SYNTHESIS OF BORONATE SALTS AND USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| EP-2825542-A1 | LIVER X RECEPTOR MODULATORS | Vitae Pharmaceuticals, Inc. (US) | 2015-01-21 | — | — | EP | disclosed |
| WO-2013138568-A1 | LIVER X RECEPTION MODULATORS | VITAE PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| EP-2576569-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | Pharma Mar S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012040242-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20030181742-A1 | Process for the preparation of pregnane derivatives | KURARAY CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1325928-A1 | PROCESS FOR THE PREPARATION OF PREGNANE DERIVATIVES | Kuraray Co., Ltd. (JP) | 2003-07-09 | — | — | EP | disclosed |
| US-5984975-A | COLORFAST, WASHFAST HAIR DYES | L'OREAL (FR) | 1999-11-16 | — | — | US | disclosed |
| US-5703266-A | OXIDATION HAIR DYES | L'OREAL (FR) | 1997-12-30 | — | — | US | disclosed |
| EP-0652742-B1 | USE OF 3-SUBSTITUTED PARA-AMINOPHENOLS FOR DYEING KERATINOUS FIBRES AND NOVEL SUBSTITUTED 3-PARA-AMINOPHENOLS | OREAL (FR) | 1997-08-27 | — | — | EP | disclosed |
| CN-1110048-A | Novel 3-substituted para-aminophenols and their use for dyeing keratin fibers | OREAL (FR) | 1995-10-11 | — | — | CN | disclosed |
| WO-1994027564-A1 | USE OF 3-SUBSTITUTED PARA-AMINOPHENOLS FOR DYEING KERATINOUS FIBRES AND NOVEL SUBSTITUTED 3-PARA-AMINOPHENOLS | L'OREAL (FR) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181742-A1 | Process for the preparation of pregnane derivatives | CYP21A2, CYP11B2, CYP17A1 | ALDH1A1 1934/4885TSHR 1634/4885TDP1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.